Abstract: A multi-signal fluorescent probe, represented by: A method for preparing the multi-signal fluorescent probe includes: (a) adding 2-methoxyphenothiazine and ethyl iodide into a mixture of dichloromethane (DCM) and acetonitrile followed by a first reaction and a first post-treatment to obtain 10-ethyl-2-methoxy-10H-phenothiazine; (b) adding boron tribromide into the 10-ethyl-2-methoxy-10H-phenothiazine under an inert gas followed by a second reaction under an ice bath and a second post-treatment to obtain 10-ethyl-10H-phenothiazin-2-ol; and (c) mixing the 10-ethyl-10H-phenothiazin-2-ol, malonic acid, zinc chloride and phosphorus oxychloride followed by a third reaction and a third post-treatment to obtain the multi-signal fluorescent probe. A use of the multi-signal fluorescent probe in the detection of intracellular ONOO? and Na2S2 is also provided.

Abstract: Compositions and methods for visualizing tissue under illumination with fusion compounds of near-infrared radiation using near IR, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are provided.

Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

Abstract: The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.

Abstract: The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery.

Abstract: A curable and radiopaque substance, a material that can be produced from same via polymerisation, a method for producing the curable substance and the cured material, and the use of the curable substance or the cured material are disclosed. The curable substance or the cured material can be used in, inter alia, orthopaedics as so-called bone cement, in particular as a tooth filling material, dental cement, dental lining material, flowable composite material (flow material) etc., as well as in diagnostic radiology. The invention also relates to the use of the curable substance generally as a construction material in an additive manufacturing process using a digital data model.

Abstract: The present invention relates to a dental composition comprising a dental filler containing a structural filler and silanated glass flakes. Furthermore, the present invention relates to the use of silanated glass flakes for preparing a dental composition.

Abstract: A dental composition comprising doped T1O2 nanoparticles, and a curable resin material, wherein the curable resin material comprises a polymer precursor component, and wherein the dopant may be one or more of, for example, N (nitrogen), Ag (silver), F (fluorine), P (phosphorus), and P04 (phosphate). A method of using the dental composition in a dental application. The dental composition may be antibacterial in the absence of visible light or UV light.

Abstract: A dental wrap is provided. The dental wrap includes an adhesive layer and a backing layer, which is characterized in that it does not contain an active ingredient. The present invention can improve the user's feeling of use by applying various flavors that were difficult to use in the tooth whitening agent.

Abstract: Provided are methods of providing a benefit to the oral cavity by administering to the oral cavity a poorly-soluble calcium compound and subsequently introducing fluoride to the oral cavity.

Abstract: Embodiments relate to a composition comprising nanohydroxyapatite (NHAP) in an amount about 0.5 wt. % to about 50 wt. % of the composition having a particle size in a range of about 20-100 nm, an abrasive, a sweetener, and a natural oil, wherein the composition does not contain glycerin and fluoride, wherein the composition is alkaline and a dental product, and wherein the natural oil is a plant product.

Abstract: The present invention is in the field of antimicrobial compositions, e.g. for personal care. In particular, the invention relates to antimicrobial compositions for oral care, such as toothpastes, comprising antimicrobial particles and a nonionic triblock copolymer. Accordingly, the present invention relates to antimicrobial compositions comprising a modified clay particle, the particle comprising an antimicrobial compound and a clay particle, and at least one a nonionic triblock copolymer. The invention further relates to the uses and methods of the antimicrobial compositions of the invention.

Abstract: The disclosure relates to systems for altering the color of the hair, comprising a pre-treatment composition comprising at least one amine-based compound and a dyeing composition comprising at least one microtube-dye composite. The disclosure also relates to methods of altering the color of the hair using the systems, as well as kits comprising the systems.

Abstract: The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto.

Abstract: A cosmetic composition with enhanced water resistance, color intensity and color retention after exposure to water is disclosed herein. The composition comprises a water dispersible film former component, a skin adhesion promoter component, a color enhancer component, and one or more colorants. The synergy of the components contributes to the improved attributes of the composition.

Abstract: Described herein are rinse-off hair conditioner compositions with high deposition properties for cationically coated microcapsules. The compositions contain limited amounts of quaternary ammonium salts that are replaced by at least one non-quaternized conditioning ingredient to provide a high deposition of microcapsules onto a surface.

Abstract: The present disclosure relates to compositions for altering the tone or color of the hair, the compositions comprising at least one amino acid, at least one carboxylic acid, monoethanolamine, and at least one hair coloring agent. The disclosure also relates to methods of using the compositions.

Abstract: Described herein is an anti-dandruff composition including at least two anti-dandruff actives selected from a punicalagin composition; a first monoterpenoid composition, or a second monoterpenoid composition; and a dermatologically-acceptable carrier. The two or more anti-dandruff actives are present in the anti-dandruff composition in an effective amount to treat or prevent dandruff caused by the proliferation of Malassezia furfur.

Abstract: A hair coloring composition that includes about 5 to 25 wt. % of a first monosaccharide having 2 to 4 carbon atoms, up to about 10 wt. % of a second monosaccharide having 2 to 4 carbon atoms, about 0.1 to 5 wt. % of a surfactant, and about 0.1 to 5 wt. % of a delivery agent, each based on a total weight of the hair coloring composition. A method for coloring hair, that involves applying the hair coloring composition onto the hair, and optionally applying heat to the hair at a dyeing temperature of 30 to 205° C.

Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Abstract: A cosmetic ink composition comprises a particulate material, a (meth)acrylic acid homopolymer or salt thereof, and a rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The (meth)acrylic acid homopolymer or salt thereof can have a weight average molecular weight of less than about 20,000 daltons. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a first dynamic viscosity of greater than about 1,100 cP at a shear rate of 0.1 sec?1 measured at 25° C. and a second dynamic viscosity of less than about 100 cP at a shear rate of 1,000 sec?1 measured at 25° C.

Abstract: A composition and a method of washing urushiol off the surface of human skin. The composition includes a first solely C12 surfactant and a second solely C12 surfactant that are each in a non-buffered composition and the composition is free of each of the following: (1) any nonylphenol ethoxylate, (2) any pharmaceutically active drug or prodrug, or (3) any salt that affects the functional characteristics of either of the solely C12 surfactants.

Abstract: A method for treating the skin of a subject in need thereof is disclosed. The method includes topically applying to the skin of the subject a cosmetic composition that includes an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract of Silybum marianum and an aqueous, alcoholic, or aqueous-alcoholic extract of Momordica grosvenori fruit.

Abstract: An underarm toner for eliminating or reducing odor-causing bacteria may include rosa damascena; water; aloe leaf juice; calendula; lemon balm; glycerin; ylang-ylang; lactic acid; lactobacillus and coconut fruit extract; lactobacillus ferment; watermelon fruit extract; chamomile extract; a probiotic blend; grapefruit seed extract; sandalwood oil; lavender oil; rosemary oil; clary sage oil; eucalyptus oil; lemon peel oil; red radish root; geranium oil; and cinnamon leaf oil. A method for eliminating body odor may include applying the underarm toner to the underarm region, causing the pH level to be maintained at about 4 to about 5, thus eliminating odor-causing bacteria from the underarm region.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: The invention relates to a metallic, nanoporous canister used to encapsulate cellular and/or biotherapeutic agents. The device is biocompatible and functions to wholly isolate a therapeutically active agent and/or cells therein. Their implantation, and survival in vivo, permits the local or systemic diffusion of their encapsulated cellular and/or biomolecular and therapeutics factors with the potential to promote repair of damaged or degenerated tissues in mammalian hosts, primarily humans.

Abstract: An improved medical implant device directed to, inter alia, (i) avoiding unwanted initial drug “burst” problems, (ii) providing a more level amount of drug delivery, (iii) reducing blood clotting, (iv) reducing the amount of drug material that remains in the implant device, and/or (v) novel materials for an implant device.

Abstract: The invention relates to a metallic, nanoporous canister used to encapsulate cellular and/or biotherapeutic agents. The device is biocompatible and functions to wholly isolate a therapeutically active agent and/or cells therein. Their implantation, and survival in vivo, permits the local or systemic diffusion of their encapsulated cellular and/or biomolecular and therapeutics factors with the potential to promote repair of damaged or degenerated tissues in mammalian hosts, primarily humans.

Abstract: A material includes a metallic, nanoporous structure having a plurality of nanopores having a porosity that allows passage of insulin but not IgG. The metallic nanoporous structure includes titanium, 316L stainless steel and may have a textured nano-sericeous surface. A nanoporous bicontinuous structure can be integrated with nanopores.

Abstract: A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed.

Abstract: Methods comprising the insertion of a uterine cervical device into the lower part of the uterine cavity and endocervix for decreasing the incidence of the human papillomavirus in women, mainly types 16 and 18, thus preventing the development of uterine cervical cancer; for modifying the cervical microbiota; for increasing leukocytes and protecting against sexually transmitted infections in women.

Abstract: The present disclosure relates to compositions and methods for treating oral pain. The compositions disclosed herein may comprise a dissolvable carrier containing at least one active ingredient. In some embodiments, the active ingredients comprise guaiacol, eugenol, glycerin, menthol oil, peppermint oil, oregano oil, and cardamom oil. The methods disclosed herein comprise treating oral pain in a subject using the compositions disclosed herein, wherein such compositions are configured as a paste that can be molded on or about a surface exhibiting oral pain in a subject's oral cavity. Such compositions are resistant to the moist environment of the subject's oral cavity and provide rapid, effective pain relief in the subject.

Abstract: The present application provides stable ready-to-use injectable formulations of melphalan, methods for preparing storage-stable, ready-to-use injectable formulations that include melphalan, which are easy to administer without need of any reconstitution step and has a desirable solubility, stability, and safety profile. In other embodiments, provided are storage-stable, ready-to-use, injectable liquid parenteral formulations that include melphalan and other pharmaceutically acceptable excipients.

Abstract: The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.

Abstract: The subject invention pertains to polyacrylate homopolymers produced from acrylolated drug monomers. The homopolymers can be produced in the form of nanoparticles. The nanoparticles comprising the homopolymers can be produced via a free radical-induced emulsion polymerization of the acrylolated drug monomers to produce an aqueous emulsion of uniformly sized nanoparticles. The homopolymers of the invention containing acrylolated antibiotic monomers can be active against Gram-positive and Gram-negative bacteria, such as Staphylococcus aureus and Escherichia coli. Accordingly, methods are provided of treating a disease, for example, an infection, by administering to a subject the homopolymers, homopolymeric nanoparticles, or emulsions containing homopolymeric nanoparticles of the invention.

Abstract: The present invention relates to a pharmaceutical liposomal composition comprising of about 0.8% w/w to about 1% w/w of docetaxel, about 30% w/w to about 38% w/w of Soya Phosphatidyl Choline, about 0.2% w/w to about 0.8% w/w of Sodium Cholesteryl Sulfate, about 61% w/w to about 68% w/w of Sucrose and a pH adjusting agent, wherein the pH of liposomal composition is less than 3.5 and the process for preparation thereof.

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.

Abstract: A method of making a modified hyaluronate composition including providing an aqueous solution of uncrosslinked hyaluronic acid or sodium hyaluronate in unbuffered 135 to 200 mM NaCl, crosslinking the uncrosslinked hyaluronic acid or sodium hyaluronate in the aqueous solution with a dialdehyde or disulfide crosslinking agent to provide crude modified hyaluronate having a soluble fraction and a crosslinked fraction with a 10% to 98% degree of crosslinking, centrifuging the crude modified hyaluronate and removing at least a portion of the soluble fraction, and optionally repeating the centrifuging and removing until the modified hyaluronate has less than 10% by weight of the soluble fraction based on the total weight of hyaluronate, with a soluble fraction polydispersity (Mw/Mn) of 1 to 1.6, an Rh of the crosslinked fraction of 150 nm to 2000 nm, and an Rz of the crosslinked fraction of 50 nm to 700 nm, wherein Rh>Rz.

Abstract: The present invention relates to a lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds, such as phenobarbital or salts thereof. The present invention also relates to an aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized pharmaceutical composition. The pharmaceutical compositions of the present disclosure have an ethanol content in the range from about 5000 ppm to about 70000 ppm. The composition of the present disclosure, in certain embodiments, is stable following two years of storage, wherein the total impurities do not exceed 0.5%. The pharmaceutical compositions of the present disclosure may be used for the treatment of neonatal seizures.

Abstract: The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.

Abstract: Compositions and methods for treating uterine fibroids are described, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.

Abstract: A UV lamp module for the ultraviolet irradiation of a substrate includes a lamp arrangement, a waterproof housing, and first and second airflow zones. The lamp arrangement includes multiple low-pressure mercury lamps each having a longitudinal axis. The waterproof housing surrounds the lamp arrangement and has a bottom side, a top side and at least two side walls connecting the bottom side and the top side to each other, and a beam exit opening on the bottom side which is closed by a beam exit window. The first airflow zone is formed in the housing and has an air supply duct with at least one air-guide for the supply of cooling air to the lamp arrangement. The second airflow zone is separated from the first airflow zone, and is formed in the housing and has an exhaust air duct for the discharge of heated cooling air.

Abstract: An apparatus for sanitising products comprising a housing comprising a bottom portion, interior walls an external portion and doors a pair of support beams, a plurality of internal conveyor belts, at least one UV-C light connected inside the housing, a first opening adapted to allow products to enter the housing for sanitisation and a second opening adapted to allow products to exit the housing after sanitisation.

Abstract: Provided is a decontamination apparatus including a base, and a source that emits UVC light at a suitable intensity to at least partially decontaminate a target object and render the target object pathogen reduced. An adjustable support is coupled to the base and includes an adjustment mechanism that can be manipulated to adjust a position of the source relative to the base. A controller is operatively connected to the source to control emission of the UVC light and establish at least one of a suitable duration of a decontamination process and a suitable intensity of UVC light to render the target object pathogen reduced.

Abstract: Described are light generating devices employing ultraviolet (UV) light emitting diodes and one or more UV active materials, such as UV reflective materials, UV scattering materials, and UV transparent materials. A UV light generation system, may include a plurality of UV light emitting diodes arranged across a surface having a diffuse UV reflective layer. The UV light generation system may be arranged to enclose a fluid pathway or may be arranged as a liner of a container or vessel for use in disinfecting, purifying, or sterilizing fluid, particles or objects in the fluid pathway, container, or vessel by exposure of the fluid, particles or objects to UV light generated by the UV light emitting diodes.

Abstract: In the COP treatment and the SOP treatment of the interior of a chamber of an aseptic filler, any cleaning liquid or aseptic water remaining in the chamber is quickly removed before spray of a sterilizer containing peracetic acid or hydrogen peroxide. A transfer device for transferring a container in the chamber of the aseptic filler is driven to remove the cleaning liquid sued for the COP treatment or the aseptic water used for the SOP treatment.

Abstract: Described herein is a disinfectant system in the form of an autonomous device for performing a disinfectant operation within an enclosed space defined by the walls, ceiling and floor of a room when a predefined condition, in the form of the absence of a human being within the room, is met. The purpose of the system is environmental decontamination and specifically to inactivate pathogenic organisms. The device includes a disinfectant module for carrying out the disinfectant operation when there is an absence of a human being within the room, and a sensing module for sensing the presence of a substantially stationary human being within the room.

Abstract: A system including groups of illuminators configured to provide adaptive irradiance within the ultraviolet spectrum to remove pathogens, particles, and anthropogenic activity from an air mass of a physical environment based on a detection of a presence of and amount of pathogens, particles, and anthropogenic activity in the air mass.

Abstract: The disclosure provides a medical sealant glue capable of promoting wound healing and a preparation method thereof. The medical sealant glue is formed by covalent cross-linking of two components after being physically mixed by a mixing tool, wherein the first component is a nucleophilic component, and the second component is an electrophilic component. The medical sealant glue has a gelation time of 1-10 s, a swelling ratio of 0-100%, a bursting strength of 100-250 mmHg, and a degradation time of 0.5-300 days. The nucleophilic component of the medical sealant glue contains exosome or hyaluronic acid and chitosan, and thus the medical sealant glue not only has the effect of promoting wound healing, but also has antibacterial and anti-infection effects.